Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIOA
Upturn stock ratingUpturn stock rating

BioAge Labs, Inc (BIOA)

Upturn stock ratingUpturn stock rating
$4.46
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BIOA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

Analysis of Past Performance

Type Stock
Historic Profit -6.07%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 674.12M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 2.88 - 26.62
Updated Date 05/15/2025
52 Weeks Range 2.88 - 26.62
Updated Date 05/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 539045726
Price to Sales(TTM) -
Enterprise Value 539045726
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 34167200
Shares Floating 1177831
Shares Outstanding 34167200
Shares Floating 1177831
Percent Insiders 3.8
Percent Institutions 32.64

ai summary icon Upturn AI SWOT

BioAge Labs, Inc

stock logo

Company Overview

overview logo History and Background

BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat aging-related diseases. Founded in 2015, it leverages a data-driven approach to identify targets and develop therapeutics that can extend healthy lifespan.

business area logo Core Business Areas

  • Drug Discovery and Development: Focuses on identifying and validating drug targets based on human aging data.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
  • Partnerships and Licensing: Collaborates with other companies and institutions to advance its pipeline and expand its reach.

leadership logo Leadership and Structure

BioAge is led by Kristen Fortney, PhD (CEO) and Eric Morgen, MD (CMO). The organizational structure includes teams dedicated to drug discovery, clinical development, and business development.

Top Products and Market Share

overview logo Key Offerings

  • BGE-1750 (azelaprag): A prolyl endopeptidase inhibitor being developed for muscle aging and other age-related conditions. Currently in Phase 2 clinical trials. Market share is not yet applicable as the product is not approved for sale. Competitors include companies developing muscle-building or anti-aging therapies, such as Juvenescence and Alkahest.
  • BGE-117 (apabetalone): A BET inhibitor being investigated for COVID-19 and aging-related diseases, in a prior collaboration with Resverlogix. Market share is not yet applicable as the product is not approved for sale. Resverlogix holds the IP and Bioage licensed it for aging related indications.

Market Dynamics

industry overview logo Industry Overview

The anti-aging industry is rapidly growing, driven by increasing life expectancy and a desire to maintain healthspan. The industry encompasses pharmaceuticals, supplements, diagnostics, and lifestyle interventions.

Positioning

BioAge is positioned as a leader in data-driven drug discovery for aging-related diseases, leveraging its proprietary human aging database to identify promising drug targets. Its competitive advantage lies in its focus on validated human targets.

Total Addressable Market (TAM)

The TAM for anti-aging therapeutics is estimated to be in the hundreds of billions of dollars, and is expected to continue to grow significantly in the coming years as the global population ages. BioAge is positioned to capture a portion of this market with its pipeline of therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary human aging database
  • Experienced management team
  • Strong intellectual property portfolio
  • Focus on validated human targets
  • Collaboration with reputable institutions

Weaknesses

  • Limited clinical trial data
  • Dependence on funding
  • High drug development costs
  • Regulatory hurdles
  • Limited marketed products

Opportunities

  • Expanding clinical trial pipeline
  • Partnerships with pharmaceutical companies
  • Acquisition of complementary technologies
  • Growing anti-aging market
  • Increasing acceptance of aging as a treatable condition

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory delays
  • Changes in healthcare policy
  • Ethical concerns related to anti-aging interventions

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • NVO
  • ABBV
  • GILD

Competitive Landscape

BioAge competes with both established pharmaceutical companies and other biotech companies developing anti-aging therapies. Its advantages include its data-driven approach and focus on validated human targets. Disadvantages include it's current private status and lack of revenue generating product.

Growth Trajectory and Initiatives

Historical Growth: BioAge has grown significantly since its founding, expanding its pipeline of drug candidates and securing funding through venture capital. Growth trajectory is high but is still at an early stage.

Future Projections: Future growth is expected to be driven by the advancement of its clinical trials, partnerships, and potential acquisitions. Analyst estimates are not publicly available due to its private status.

Recent Initiatives: Recent initiatives include securing funding for Phase 2 trials of BGE-1750 and expanding its collaborations with research institutions. They have added data and targets to their Discovery program.

Summary

BioAge Labs, Inc. is a promising biotechnology company with a unique approach to developing anti-aging therapies. Its data-driven drug discovery platform and focus on validated human targets position it well for future growth. Key strengths include its proprietary database and experienced management team. However, the company faces challenges related to clinical trial risks, regulatory hurdles, and competition from larger pharmaceutical companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • BioAge Labs, Inc. website
  • Company press releases
  • Third-party industry reports and analysis
  • SEC filings of key competitors

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximations based on available data and may not be precise. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioAge Labs, Inc

Exchange NASDAQ
Headquaters Richmond, CA, United States
IPO Launch date 2024-09-26
Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Kristen Fortney Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 62
Full time employees 62

BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.